GSK expanded access to the Tempus patient data platform for drug discovery and trial design
$70 million
USD per deal (one contract), US
“GlaxoSmithKline (GSK) announced Tuesday morning it has struck a $70 million deal with Tempus in exchange for expanded access to Tempus”
BioSpace, GSK Expands AI Footprint with $70M Tempus Deal (18 October 2022), 2022-10
- Kind of source
- Named press report
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- Reported deal value for platform access, not a per-record price. The term and the split between data and software are not in this quote.
Used in
Kept as evidence; no figure on the platform is computed from it yet.